United Therapeutics Corporation

NasdaqGS:UTHR Stock Report

Market Cap: US$13.8b

United Therapeutics Past Earnings Performance

Past criteria checks 2/6

United Therapeutics has been growing earnings at an average annual rate of 22.5%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 15.9% per year. United Therapeutics's return on equity is 17.8%, and it has net margins of 40.4%.

Key information

22.54%

Earnings growth rate

21.74%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate15.85%
Return on equity17.79%
Net Margin40.44%
Next Earnings Update30 Jul 2025

Recent past performance updates

Recent updates

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Jul 22
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

United Therapeutics: A Cheap But Complicated Tale

Jun 06

Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?

May 11
Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?

Investors Aren't Buying United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Apr 23
Investors Aren't Buying United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Apr 05
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

United Therapeutics: A Unique Business With High Margins And Expansion Potential

Feb 25

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Feb 05
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics Corporation (NASDAQ:UTHR) Doing What It Can To Lift Shares

Jan 18
United Therapeutics Corporation (NASDAQ:UTHR) Doing What It Can To Lift Shares

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Dec 10
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
author-image

Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership

Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.

United Therapeutics: Economics Support Compounding Ability

Aug 20

United Therapeutics: Exciting Company With A Big Problem

Jun 02

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Revenue & Expenses Breakdown

How United Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:UTHR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 252,9941,211666526
31 Dec 242,8771,195640481
30 Sep 242,7561,111607499
30 Jun 242,6171,069581480
31 Mar 242,4981,051533429
31 Dec 232,328985476408
30 Sep 232,204900499351
30 Jun 232,111872470332
31 Mar 231,981728481337
31 Dec 221,936727473323
30 Sep 221,860707448312
30 Jun 221,789631458324
31 Mar 221,768687429304
31 Dec 211,686476466410
30 Sep 211,655462499450
30 Jun 211,591471451440
31 Mar 211,506405444456
31 Dec 201,483515421358
30 Sep 201,410469364345
30 Jun 201,431430402362
31 Mar 201,443528336350
31 Dec 191,449-1043351,174
30 Sep 191,519-923131,199
30 Jun 191,530-1183241,214
31 Mar 191,601-1503671,220
31 Dec 181,628589269358
30 Sep 181,711543348333
30 Jun 181,744713285287
31 Mar 181,744484270264
31 Dec 171,725418333265
30 Sep 171,670509311218
30 Jun 171,632395363209
31 Mar 171,600657368184
31 Dec 161,599714319148
30 Sep 161,595708326157
30 Jun 161,5731,011209120
31 Mar 161,507904246135
31 Dec 151,466652453245
30 Sep 151,407663385241
30 Jun 151,351173604350
31 Mar 151,327186562340
31 Dec 141,289340381243
30 Sep 141,231194458293

Quality Earnings: UTHR has high quality earnings.

Growing Profit Margin: UTHR's current net profit margins (40.4%) are lower than last year (42%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: UTHR's earnings have grown significantly by 22.5% per year over the past 5 years.

Accelerating Growth: UTHR's earnings growth over the past year (15.2%) is below its 5-year average (22.5% per year).

Earnings vs Industry: UTHR earnings growth over the past year (15.2%) did not outperform the Biotechs industry 21.7%.

Return on Equity

High ROE: UTHR's Return on Equity (17.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/25 21:18
End of Day Share Price 2025/07/25 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

United Therapeutics Corporation is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company